Article Information
vol. 42 no. 1 156-168
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 27, 2012
- Accepted October 5, 2012
- Published online June 30, 2013.
Article Versions
- previous version (October 25, 2012 - 14:24).
- You are viewing the most recent version of this article.
Copyright & Usage
©ERS 2013
Author Information
- Dennis Falzon1,
- Neel Gandhi2,
- Giovanni B. Migliori3,
- Giovanni Sotgiu4,
- Helen S. Cox5,
- Timothy H. Holtz6,
- Maria-Graciela Hollm-Delgado7,
- Salmaan Keshavjee8,
- Kathryn DeRiemer9,
- Rosella Centis3,
- Lia D'Ambrosio3,
- Christoph G. Lange10,
- Melissa Bauer7,11 and
- Dick Menzies7⇑
- on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB12
- 1Stop TB Dept, World Health Organization, Geneva, Switzerland
- 2Divisions of General Internal Medicine, Infectious Diseases and Epidemiology, Albert Einstein College of Medicine, New York, NY
- 8Dept of Global Health and Social Medicine, Harvard Medical School, Boston, MA
- 9School of Medicine, University of California Davis, Davis, CA, USA
- 3World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate
- 4Dept of Biomedical Sciences, University of Sassari, Sassari, Italy
- 5Médecins Sans Frontières, Cape Town, South Africa
- 6US Centers for Disease Control and Prevention, HIV/STD Research Program, Bangkok, Thailand
- 10Clinical Infectious Diseases, Tuberculosis Center Borstel, Borstel, Germany
- 11Dept of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC
- 7Montreal Chest Institute, McGill University, Montreal, QC, Canada
- 12A full list of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB members and their affiliations can be found in the Acknowledgements
- D. Menzies, Montréal Chest Institute, 3650 St Urbain St., Montréal, PQ, H2X 2P4, Canada. E-mail: Dick.Menzies{at}McGill.ca
Article usage
Altmetrics
Vol 42 Issue 1
Table of Contents
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
